Last reviewed · How we verify
SNG001
SNG001 is an inhaled interferon beta-1a, which works by stimulating the body's immune response to fight off respiratory viruses.
SNG001 is an inhaled interferon beta-1a, which works by stimulating the body's immune response to fight off respiratory viruses. Used for Treatment of COVID-19.
At a glance
| Generic name | SNG001 |
|---|---|
| Sponsor | Synairgen Research Ltd. |
| Drug class | Interferon |
| Target | IFNAR |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
It does this by activating the JAK-STAT signaling pathway, which leads to the production of antiviral proteins and the recruitment of immune cells to the site of infection. This helps to reduce the severity and duration of respiratory illnesses such as COVID-19.
Approved indications
- Treatment of COVID-19
Common side effects
- Headache
- Fatigue
- Cough
- Nausea
Key clinical trials
- Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection (PHASE2)
- ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2, PHASE3)
- Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 (PHASE3)
- A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza (PHASE2)
- Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection (PHASE2)
- Comparing Efficacy and Safety of Inhaled SNG001 to Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SNG001 CI brief — competitive landscape report
- SNG001 updates RSS · CI watch RSS
- Synairgen Research Ltd. portfolio CI